{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:39:51Z","timestamp":1790487591156,"version":"4.1.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,28]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>TKI-resistant CML patients display persistent BMP pathway alterations in leukemic immature cells and their niche. A subpopulation of TKI-resistant leukemic stem cells survives through binding of BMP4 to BMPR1b, which preserves TWIST-1-expressing cells.<\/jats:p>","DOI":"10.1182\/blood-2017-08-801019","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T16:35:07Z","timestamp":1510677307000},"page":"2860-2871","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Immature CML cells implement a BMP autocrine loop to escape TKI treatment"],"prefix":"10.1182","volume":"130","author":[{"given":"Elodie","family":"Grockowiak","sequence":"first","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Laperrousaz","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"},{"name":"CNRS UMR 5672, Ecole Normale Sup\u00e9rieure de Lyon, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Jeanpierre","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"},{"name":"Centre L\u00e9on B\u00e9rard, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Voeltzel","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Guyot","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gobert","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck E.","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"},{"name":"Centre L\u00e9on B\u00e9rard, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Maguer-Satta","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique (CNRS) Unit\u00e9 Mixte de Recherche (UMR) and"},{"name":"INSERM Unit\u00e9 1052, Centre de Recherche en Canc\u00e9rologie de Lyon (CRCL), Lyon, France;"},{"name":"Universit\u00e9 de Lyon, Lyon, France;"},{"name":"Department of Signaling of Tumor Escape, CRCL, Lyon, France;"},{"name":"French Group of Chronic Myeloid Leukemia (CML) (Fi-LMC), Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2019111903581410800_B1","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019111903581410800_B2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"2019111903581410800_B3","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2019111903581410800_B4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"26","key":"2019111903581410800_B5","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111903581410800_B6","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111903581410800_B7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"20","key":"2019111903581410800_B8","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111903581410800_B9","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111903581410800_B10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2019111903581410800_B11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111903581410800_B12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111903581410800_B13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7569","key":"2019111903581410800_B14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"issue":"11","key":"2019111903581410800_B15","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/bjc.2012.142","article-title":"Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations","volume":"106","author":"Glauche","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"2019111903581410800_B16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.12532","article-title":"Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up","volume":"163","author":"Gallipoli","year":"2013","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111903581410800_B17","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2013-05-501460","article-title":"Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression","volume":"122","author":"Laperrousaz","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111903581410800_B18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1042\/BST20140037","article-title":"The role of the bone morphogenetic proteins in leukaemic stem cell persistence","volume":"42","author":"Toofan","year":"2014","journal-title":"Biochem Soc Trans"},{"issue":"5","key":"2019111903581410800_B19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.18632\/oncotarget.990","article-title":"Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations","volume":"4","author":"Gerber","year":"2013","journal-title":"Oncotarget"},{"issue":"107","key":"2019111903581410800_B20","first-page":"mr1","article-title":"BMPs: from bone to body morphogenetic proteins","volume":"3","author":"Wagner","year":"2010","journal-title":"Sci Signal"},{"issue":"13","key":"2019111903581410800_B21","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1101\/gad.10.13.1580","article-title":"Bone morphogenetic proteins: multifunctional regulators of vertebrate development","volume":"10","author":"Hogan","year":"1996","journal-title":"Genes Dev"},{"issue":"5","key":"2019111903581410800_B22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood-2012-07-446443","article-title":"A novel role of BMP4 in adult hematopoietic stem and progenitor cell homing via Smad independent regulation of integrin-\u03b14 expression","volume":"121","author":"Khurana","year":"2013","journal-title":"Blood"},{"issue":"6960","key":"2019111903581410800_B23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nature02041","article-title":"Identification of the haematopoietic stem cell niche and control of the niche size","volume":"425","author":"Zhang","year":"2003","journal-title":"Nature"},{"issue":"6","key":"2019111903581410800_B24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1089\/scd.2006.15.805","article-title":"Bone morphogenetic protein 4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex vivo stroma-noncontact co-culture system","volume":"15","author":"Hutton","year":"2006","journal-title":"Stem Cells Dev"},{"issue":"8","key":"2019111903581410800_B25","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-03-145326","article-title":"BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling","volume":"112","author":"Jeanpierre","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111903581410800_B26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0014-4827(02)00013-7","article-title":"Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family","volume":"282","author":"Maguer-Satta","year":"2003","journal-title":"Exp Cell Res"},{"issue":"24","key":"2019111903581410800_B27","doi-asserted-by":"crossref","first-page":"12675","DOI":"10.18632\/oncotarget.2564","article-title":"A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy","volume":"5","author":"Raymond","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"2019111903581410800_B28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.stemcr.2014.12.007","article-title":"Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response","volume":"4","author":"Chapellier","year":"2015","journal-title":"Stem Cell Reports"},{"issue":"1","key":"2019111903581410800_B29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/cdd.2016.107","article-title":"Long-term exposure to bisphenol A or benzo(a)pyrene alters the fate of human mammary epithelial stem cells in response to BMP2 and BMP4, by pre-activating BMP signaling","volume":"24","author":"Cl\u00e9ment","year":"2017","journal-title":"Cell Death Differ"},{"issue":"50","key":"2019111903581410800_B30","doi-asserted-by":"crossref","first-page":"E6882","DOI":"10.1073\/pnas.1507899112","article-title":"Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2","volume":"112","author":"Choi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111903581410800_B31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ccr.2007.12.005","article-title":"Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells","volume":"13","author":"Lee","year":"2008","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111903581410800_B32","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood-2009-11-254680","article-title":"Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia","volume":"117","author":"Cosset","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2019111903581410800_B33","doi-asserted-by":"crossref","first-page":"20977","DOI":"10.18632\/oncotarget.4007","article-title":"TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"2019111903581410800_B34","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/bcj.2014.22","article-title":"The emerging role of Twist proteins in hematopoietic cells and hematological malignancies","volume":"4","author":"Merindol","year":"2014","journal-title":"Blood Cancer J"},{"issue":"3","key":"2019111903581410800_B35","first-page":"229","article-title":"Direct activation of Bmi1 by Twist1: implications in cancer stemness, epithelial-mesenchymal transition, and clinical significance","volume":"34","author":"Wu","year":"2011","journal-title":"Chang Gung Med J"},{"issue":"Pt 8","key":"2019111903581410800_B36","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1242\/jcs.000067","article-title":"Comparative roles of Twist-1 and Id1 in transcriptional regulation by BMP signaling","volume":"120","author":"Hayashi","year":"2007","journal-title":"J Cell Sci"},{"issue":"6","key":"2019111903581410800_B37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111903581410800_B38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070.015k17_1070_1079","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2019111903581410800_B39","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019111903581410800_B40","article-title":"Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015) (published online ahead of print 4 Aug 2016)","author":"Hopkins","journal-title":"Expert Opin Ther Pat"},{"issue":"8","key":"2019111903581410800_B41","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3324\/haematol.2017.167080","article-title":"Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib","volume":"102","author":"Gullaksen","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"2019111903581410800_B42","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2019111903581410800_B43","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/nm.3364","article-title":"Differential regulation of myeloid leukemias by the bone marrow microenvironment","volume":"19","author":"Krause","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"2019111903581410800_B44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2003-08-2695","article-title":"Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia","volume":"104","author":"Legros","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111903581410800_B45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","article-title":"Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells","volume":"27","author":"Welner","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111903581410800_B46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/leu.2011.291","article-title":"Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn\/CXCR4 interactions in lipid rafts","volume":"26","author":"Tabe","year":"2012","journal-title":"Leukemia"},{"issue":"23","key":"2019111903581410800_B47","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","article-title":"Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111903581410800_B48","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","article-title":"Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations","volume":"123","author":"Traer","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111903581410800_B49","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111903581410800_B50","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1042\/BST20160104","article-title":"Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis","volume":"44","author":"Toofan","year":"2016","journal-title":"Biochem Soc Trans"},{"issue":"12","key":"2019111903581410800_B51","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2019111903581410800_B52","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","article-title":"Leukemia propagating cells rebuild an evolving niche in response to therapy","volume":"25","author":"Duan","year":"2014","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/26\/2860\/1403662\/blood801019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/26\/2860\/1403662\/blood801019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:58:36Z","timestamp":1574135916000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/26\/2860\/36599\/Immature-CML-cells-implement-a-BMP-autocrine-loop"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":52,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-08-801019","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,28]]}}}